Nextensa SA: RESULTATS SEMESTRIELS 2025 COMMUNIQUÉ DE PRESSE INFORMATION REGLEMENTÉE Bruxelles, 13 août 2025, 17h40 Des résultats semestriels solides confirment la stratégie de Nextensa Au premier semestre 2025, Nextensa a enregistré une nette augmentation de sa rentabilité malgré un contexte économique difficile. Le résultat net a fortement progressé, porté par une contribution plus élevée des activités de développement, des coûts de financement réduits et un renforcement supplémentaire du bilan. Les revenus locatifs sous-jacents ont affiché une croissance positi...
Nextensa NV: HALFJAAR RESULTATEN 2025 PERSBERICHT GEREGLEMENTEERDE INFORMATIE Brussel, 13 augustus 2025, 17u40 Solide halfjaarresultaten bevestigen strategische koers van Nextensa In de eerste helft van 2025 realiseerde Nextensa een duidelijke toename van de winstgevendheid, ondanks een uitdagende economische context. Het nettoresultaat steeg aanzienlijk, gedreven door een hogere bijdrage van de ontwikkelingsactiviteiten, lagere financieringskosten en een verdere versterking van de balans. De onderliggende huurinkomsten kenden een positieve like-for-like groei, voorna...
Nextensa NV/SA: Half Year results 2025 PRESS RELEASE REGULATED INFORMATIONBrussels, 13 August 2025, 5:40 PM Solid half-year results confirm Nextensa’s strategic course In the first half of 2025, Nextensa achieved a clear increase in profitability despite a challenging economic context. Net profit increased significantly, driven by a higher contribution from development activities, lower financing costs, and a further strengthening of the balance sheet. Underlying rental income recorded positive like-for-like growth, mainly thanks to improved occupancy at Moonar and Tour & Taxis...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), August 12, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total a...
We zoom in on the deal announced between HOMI and City Forward. HOMI will redevelop 8 offices into 700-750 apartments over the next 7-9 years. The deal will push the residential portfolio of HOMI over EUR 1.2B. We assume a total investment of EUR 280.0m, 20% development margin and EUR 14.0m gross rental income. We are very supportive of this deal but the gains on the development are back-end loaded while we see a short term headwind in a building right expiry in Louvain La Neuve (10.9% rents). ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), August 5, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total am...
AB InBev: 2Q25 results. Air France-KLM: Nice beat, let's see how FY25 finishes. AMG: Uptrend continues in 2Q25 with 23% EBITDA beat and guidance up to +US$200m. Aperam: Slight 2Q25 EBITDA beat, 3Q25 seen down QoQ. Arcadis: EBITA margin held up well in 2Q25, order intake mixed. Ayvens: 2Q25 results. Azelis: Soft but largely in-line 2Q25 with EMEA offsetting weaker APAC. Bekaert: 1H25 miss and lowered outlook to result in c.5% consensus downside. Corbion: Taking it to the wire. dsm...
dsm-firmenich reports H1 2025 results Press ReleaseKaiseraugst (Switzerland), Maastricht (Netherlands), July 31, 2025 dsm-firmenich reports H1 2025 results Management Report H1 2025 highlights Good first half of the year, with good organic sales and earnings growthProgressing well on 2025 strategic planCompletion of sale of Feed Enzymes business for €1.5 billion on June 2, 2025€1 billion share buyback program commenced in April 2025, and completion accelerated to January 2026Animal Nutrition & Health exit process advancingFY 2025 outlook updated: Adjusted EBITDA around €2.4 billion Ke...
Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...
Elia delivered stellar 1H25 results, although driven by some exceptional factors that will be partly compensated in the 2H25 results. Mainly the shift to pro-rata accounting of the GE Capex had a large €40m positive impact. Also capitalising more interest as investments increase, had a positive effect on ETB as well as 50Hz. After the 2.2bn equity issue, Elia recovered sharply from the overhang uncertainty to trade back in line with the BEL-20 index. However, the equity raise at €61.9 per share ...
Weekly progress on share repurchase program to cover share plans and reduce capital Press Release Weekly progress on share repurchase program to cover share plans and reduce capital Kaiseraugst (Switzerland), Maastricht (Netherlands), July 29, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, announced on February 13, 2025 its intention to repurchase ordinary shares with an aggregate market value of €1 billion and reduce its issued capital, starting with an initial €500 million. On April 1, 2025, the company commenced a program to repurchase ordinary shares for a total amo...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.